NEW YORK (GenomeWeb News) – Dalton Pharma Services will use Thermo Fisher Scientific’s enzyme-based technology to make nucleic acid biopolymers for use in drug development research projects, Toronto-base Dalton said today.
Dalton will produce poly-inosine and poly-cytosine in accordance with current good manufacturing practice regulations.
These polynucleotides are used as catalysts to stimulate immune responses when they are combined with other substances in a drug, the company said.
Dalton also said it plans to supply these polynucleotides to the pharmaceutical company Oncovir, which will use them in vaccine development projects.
Financial terms of the agreement were not released.